Skip to main content
. Author manuscript; available in PMC: 2014 Jul 29.
Published in final edited form as: Cancer Res. 2009 Aug 25;69(17):6932–6940. doi: 10.1158/0008-5472.CAN-09-1682

Figure 2.

Figure 2

Selective targeting of PSMA in vivo with [123I]-MIP-1072 and [123I]-MIP-1095. Radiolabeled compound was injected into mice bearing LNCaP xenografts and imaged by SPECT/CT at 4 hr (top) or mice bearing PC3 PIP (PSMA +) or PC3 flu (PSMA −) xenografts and imaged by SPECT/CT at 2 hr (bottom). Each mouse was injected with approximately 1 mCi of radiolabeled compound at a specific activity >1000 mCi/µmol.